Nutrition 21 (NXXI) soared 22% Tuesday after the company said a study showed its Selenomax product stopped progression of the HIV virus.

The Purchase, N.Y., company said the benefits were reported in a five-year, double-blind, placebo-controlled study conducted by researchers at the University of Miami and published in the Jan. 22 issue of the American Medical Association's Archives of Internal Medicine.

Shares were rising 41 cents to $2.30.

More from Stocks

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain